ADA Scientific Sessions Recap—Day #3: Dan Finan, Ph.D.
There was some really amazing results out here in San Francisco! Here is Dan Finan, Ph.D., head of the Breakthrough…
First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset
This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune…
ADA Scientific Sessions – The Second Day: Andrew Rakeman, Ph.D.
We’re at the 2019 American Diabetes Association Scientific Sessions, and there’s so much to learn! Here is the recap from…
Sanjoy Dutta, Ph.D.: The Beginning of the ADA Scientific Sessions
The ADA’s Scientific Sessions has begun! Here, in the first recap, is Sanjoy Dutta, Ph.D., who highlights beta cell replacement…
Breakthrough T1D Heads to ADA’s 79th Scientific Sessions
The American Diabetes Association’s (ADA) 79th Scientific Sessions is almost here! From June 7-11, in San Francisco, CA, scientists and…
Breakthrough T1D Urges Congress to Fund Diabetes Research
On June 4, Breakthrough T1D’s President & CEO Aaron J. Kowalski, Ph.D., testified before the U.S. House of Representatives Committee…
Breakthrough T1D Beta Cell Replacement Consortium: Sharing data and resources, saving time and money
The Breakthrough T1D Spring Beta Cell Replacement Consortium meeting, held recently in NYC, allowed 55 researchers from a diversity of…
Proof-of-Concept for Hypoglycemia Prevention
Hypoglycemia, or low blood sugar, can have serious effects, and it is, for most people with type 1 diabetes (T1D),…
T1D Fund Featured in WSJ as Part of Innovative Quest for Cures
Breakthrough T1D’s innovative approach to driving more funds into type 1 diabetes (T1D) medical advances caught the attention of the…
Breakthrough T1D Research Strategy: Cures and Improving Lives
They shared new developments and applauded the speed of scientific advancements. At this year’s Strategic Research Session, the tone was…
